fbpx

Year

2014
SAN DIEGO, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced it has appointed Scott Garrett as Vice President, Commercial Planning, a newly created position.
PREHISTORIC MIGRATIONS. We know people have lived in the New World Arctic for about 5,000 years. Archaeological evidence clearly shows that a variety of cultures survived the harsh climate in Alaska, Canada and Greenland for thousands of years. Despite this, there are several unanswered questions about these people: Where did they come from? Did they...
A conference call will be held tomorrow, 21 August, 2014 at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM EST (New York).To access the live conference call, please dial one of the following numbers:+45 32 72 80 18+45 32 72 80 18 (Denmark)44 (0) 1452 555 131 (UK)+1 866 682 84901 866 682...
SAN DIEGO, Aug. 18, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the closing of its underwritten public offering of 4,600,000 shares of its common stock at $9.50 per share, including 600,000 shares sold pursuant to the...
SAN DIEGO, Aug. 12, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at $9.50 per share. The gross proceeds to Celladon from this...
SAN DIEGO, Aug. 11, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that the first patient has been dosed in a clinical trial titled “Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients with...
SAN DIEGO, Aug. 7, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced financial results for the quarter ended June 30, 2014 and recent highlights. “We have had very positive recent developments with MYDICAR. Last quarter’s FDA Breakthrough...
SAN DIEGO, Aug. 7, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it is offering to sell 4,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Celladon will also...
1 2 3 4 5 8

News

Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020
Ancient DNA throws a ‘scientific hand grenade’ into the discussion about the arrival of humans in North America
23. July 2020
Danish researchers map key disease mechanism – and describe a completely new protein
20. July 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge